Micron Technologies Inc. has selected a site in Malvern Pennsylvania to build new plant.
Plans are currently being developed for the construction of an 85,000 square feet facility.
The facility will house a state of art laboratories and mill rooms. Estimated opening early 2010

A full isolator system for machinery has been installed at Micron’s US facility.
This new system provides Micron the capability to handle potent compounds with   OEL’s of 100 nanograms.

May 2007 Micron Technologies Inc. Exton Pennsylvania facility successfully completed an inspection from FDA.

Micron Technologies Inc. has increased its laboratory capacity by more than 50% in order to support the growing requirements coming from its customers for Material Characterisation; additional HPLCs, Differential Scanning Calorimetry, BET and microscope have been added to the existing equipments.

Both facilities have now the possibility to micronise potent compounds under 100 nanogram OEL in an in-house developed containment system which allow the micronisation of R&D quantities as well as commercial quantities

January 2007 -- Micron Technologies UK facility in Dartford, Kent successfully completed its latest inspection from the MHRA

October 10, 2005 -- Micron Technologies UK facility in Dartford, Kent successfully completed its latest inspection from the FDA

The American Food and Drug Administration had two inspector audit the facility over three days in October 2005. This success highlights the commitment to quality by Micron Technologies continues the ongoing programme of audit and inspection from customers, FDA, EMEA and MHRA at our facilities.

October 2, 2005 -- Article by Peter Nelson, Analytical Services Manager Micron Technologies Inc.
                                  "Developing a Robust and Repeatable Particle Size Analysis Method -- Part 1"

DRRPSAM_2005_Part1.pdf

September 10, 2005 -- Article by Jean Martin Larran, General Manager Micron Technologies Ltd.
                                                 "Micronisation of Pharmaceutical Powders for Use in Inhalation"

Due to the nature of the respiratory tract, depending on the indication for which the product is being developed, particle size of pharmaceutical powders for use in inhalation is critical. It will dictate which areas of the respiratory tract are targeted in order for the product to have the greatest efficacy. This article will cover different micronisation techniques used by the industry to achieve desired particle size, and will describe analytical techniques to test these particles and characterize the powders.

PMPS_Spring_2005_Micron.pdf

November 2005 -- Micron Technologies Inc completes Expansion

Micron Technologies Inc has begun an expansion to its Facility in Exton Pennsylvania. The expansion will increase existing capacity by 50% and includes two new processing suites. The new processing suites are based on a similar design used in Micron’s facility located in the United Kingdom. The new processing suites will be totally redundant and will not impact Micron’s ability to meet client demands during this construction phase. The expansion was completed and operational by November of 2005.

According to Brian Hausner, president, “the expansion supports Micron’s overall strategy of maintaining capacity ahead of customer demand. The pharmaceutical industry’s business model is evolving and Micron will continue to invest in services that support the industry.”

Micron Technologies Inc provides contract particle size reduction and analytical laboratory services exclusively for the pharmaceutical industry. With compatible FDA inspected facilities located in the United States and the United Kingdom. Project scale up and processing can be undertaken in both facilities. Analytical capabilities include but are not limited to; particle size analysis, surface area, XRD, microscopy, method development, and release testing.
 

Other News:

Micron has the following NEW capabilities: